3SBio Inc
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER… Read more
Market Cap & Net Worth: 3SBio Inc (83B)
3SBio Inc (F:83B) has a market capitalization of $6.01 Billion (€5.85 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #3015 globally and #268 in its home market, demonstrating a 12.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 3SBio Inc's stock price €2.48 by its total outstanding shares 2359228724 (2.36 Billion).
3SBio Inc Market Cap History: 2015 to 2026
3SBio Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.25 Billion to $6.01 Billion (18.90% CAGR).
3SBio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 3SBio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.19x
3SBio Inc's market cap is 0.19 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.85x
3SBio Inc's market cap is 0.85 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $894.57 Million | $2.80 Billion | $712.56 Million | 0.32x | 1.26x |
| 2017 | $1.60 Billion | $3.73 Billion | $935.39 Million | 0.43x | 1.71x |
| 2018 | $1.13 Billion | $4.58 Billion | $1.28 Billion | 0.25x | 0.88x |
| 2019 | $1.21 Billion | $5.32 Billion | $973.72 Million | 0.23x | 1.24x |
| 2020 | $759.92 Million | $5.59 Billion | $835.79 Million | 0.14x | 0.91x |
| 2021 | $704.71 Million | $6.38 Billion | $1.65 Billion | 0.11x | 0.43x |
| 2022 | $1.44 Billion | $6.86 Billion | $1.91 Billion | 0.21x | 0.75x |
| 2023 | $1.32 Billion | $7.82 Billion | $1.55 Billion | 0.17x | 0.85x |
| 2024 | $1.77 Billion | $9.11 Billion | $2.09 Billion | 0.19x | 0.85x |
Competitor Companies of 83B by Market Capitalization
Companies near 3SBio Inc in the global market cap rankings as of March 18, 2026.
Key companies related to 3SBio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
3SBio Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, 3SBio Inc's market cap moved from $1.25 Billion to $ 6.01 Billion, with a yearly change of 18.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.01 Billion | -6.06% |
| 2025 | €6.39 Billion | +261.64% |
| 2024 | €1.77 Billion | +33.92% |
| 2023 | €1.32 Billion | -8.05% |
| 2022 | €1.44 Billion | +103.71% |
| 2021 | €704.71 Million | -7.27% |
| 2020 | €759.92 Million | -37.29% |
| 2019 | €1.21 Billion | +7.27% |
| 2018 | €1.13 Billion | -29.28% |
| 2017 | €1.60 Billion | +78.56% |
| 2016 | €894.57 Million | -28.29% |
| 2015 | €1.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of 3SBio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.01 Billion USD |
| MoneyControl | $6.01 Billion USD |
| MarketWatch | $6.01 Billion USD |
| marketcap.company | $6.01 Billion USD |
| Reuters | $6.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.